Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Egetis Therapeutics

4.77 SEK

+1.27 %

Less than 1K followers

EGTX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+1.27 %
+7.67 %
-10.67 %
-9.66 %
-11.17 %
-4.31 %
-14.97 %
-30.22 %
-65.53 %

Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.

Read more
Market cap
2.02B SEK
Turnover
866.53K SEK
Revenue
46.1M
EBIT %
-714.53 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/2
2026

Annual report '25

29/4
2026

Interim report Q1'26

6/5
2026

General meeting '26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Egetis Therapeutics, Audiocast, Q4'25
Webcast2/26/2026, 9:00 AM

Egetis Therapeutics, Audiocast, Q4'25

Egetis Therapeutics
Press releaseyesterday

Inbjudan till presentation av Egetis kvartalsrapport Q4 och bokslutskommuniké 2025 den 26 februari 2026

Egetis Therapeutics
Press releaseyesterday

Invitation to presentation of Egetis’ fourth quarter and year-end 2025 report on February 26, 2026

Egetis Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2/16/2026, 6:00 AM

Egetis uppdaterar om framsteg med utvecklingen av Emcitate® (tiratricol) för MCT8-brist i Japan

Egetis Therapeutics
Press release2/16/2026, 6:00 AM

Egetis provides update on progress with the development of Emcitate® (tiratricol) for MCT8 deficiency in Japan

Egetis Therapeutics
Press release2/4/2026, 2:25 PM

FDAs program för prioriterad granskning av sällsynta pediatriska sjukdomar förlängt till 2029

Egetis Therapeutics
Press release2/4/2026, 2:25 PM

FDA's rare pediatric disease priority review program extended until 2029

Egetis Therapeutics
Regulatory press release1/29/2026, 6:00 AM

Egetis slutför rullande ansökan om marknadsgodkännande (NDA) i USA för Emcitate® (tiratricol) för behandling av MCT8-brist

Egetis Therapeutics
Regulatory press release1/29/2026, 6:00 AM

Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency

Egetis Therapeutics
Press release1/16/2026, 11:45 AM

Egetis Therapeutics styrelseordförande förvärvar aktier

Egetis Therapeutics
Press release1/16/2026, 11:45 AM

Chairman of the Board of Egetis Therapeutics acquires shares

Egetis Therapeutics
Press release1/8/2026, 8:30 AM

Egetis Therapeutics kommer att hålla möten i San Francisco under veckan för J.P. Morgan Healthcare Conference

Egetis Therapeutics
Press release1/8/2026, 8:30 AM

Egetis Therapeutics to Host Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Egetis Therapeutics
Regulatory press release12/30/2025, 7:00 AM

Ändring av antalet stamaktier och röster i Egetis Therapeutics

Egetis Therapeutics
Regulatory press release12/30/2025, 7:00 AM

Change in the number of ordinary shares and votes in Egetis Therapeutics

Egetis Therapeutics
Regulatory press release12/19/2025, 6:00 AM

Egetis Therapeutics inleder NDA ansökan i USA för Emcitate® (tiratricol) vid MCT8-brist

Egetis Therapeutics
Regulatory press release12/19/2025, 6:00 AM

Egetis Therapeutics initiates New Drug Application in the USA for Emcitate® (tiratricol) for MCT8 deficiency

Egetis Therapeutics
Press release12/17/2025, 12:35 PM

Egetis Therapeutics flyttas till Nasdaq Stockholms Mid Cap-segment

Egetis Therapeutics
Press release12/17/2025, 12:35 PM

Egetis Therapeutics to move to the Nasdaq Stockholm Mid Cap segment

Egetis Therapeutics
Press release12/10/2025, 6:00 AM

Egetis and Er-Kim Expand Partnership to Broaden Access to Emcitate® Across Central, Eastern, and Southeastern Europe

Egetis Therapeutics
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.